Accelerating the clinical experiment of "Hepatitis B vaccine" in Chongqing beer

Today (June 5), Chongqing Beer (600132, closing price of 37.08 Yuan) released the "treatment (synthetic peptide) Hepatitis B vaccine" research progress.　　The company said that the subsidiary of Chongqing Jia Chen Bioengineering Co., Ltd. will be held in Chongqing on June 5, 2010, the treatment of (synthetic peptide) Hepatitis B vaccine Phase II clinical research center start-up meeting.　　The meeting will be "therapeutic (synthetic peptide) hepatitis B vaccine combined with entecavir treatment of chronic hepatitis B patients with the efficacy and safety of the randomized, the specific program of Double-blind and multicenter Phase II clinical study includes a discussion on the organization of the subjects ' recruitment, the recruitment conditions of subjects, and the process management of clinical trials. According to the meeting, the clinical units affiliated with the first hospital of Zhejiang University Medical School will be recruited to initiate the above-mentioned clinical trials in the near future, the company said. At present, a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study of the efficacy and safety of "therapeutic (synthetic peptide) hepatitis B vaccine for the treatment of chronic hepatitis B in the center of the People's Hospital of Peking University" is conducting clinical trials in 16 hospitals nationwide,　　The recruitment of volunteers was completed as planned on April 15, 2010. At present, the clinical trial of the second phase B of the therapeutic (synthetic peptide) Hepatitis II vaccine is completed, and the therapeutic (synthetic peptide) Hepatitis B vaccine Phase II clinical trial was launched in February 2009 with a total of 16 clinical trial centres. The company's 2009 annual report showed that the second phase clinical trial of the treatment of hepatitis B vaccine has been in the group of 350 people, which has shown that the safety of the vaccine is effectively validated.　　In addition, the treatment of hepatitis B vaccine compared with the current hepatitis B drug has a clear advantage, in addition to better treatment, side effects are lower, the withdrawal of the basic does not rebound, and clinical experts generally agree with the treatment (synthetic peptide) safety, and the effectiveness of its full of expectations. In accordance with Phase II clinical trial programme subjects were selected, within six months to complete the 6-pin injection and observe the 48-week calculation, China Securities speculated that, if not unexpected, therapeutic (synthetic peptide) Hepatitis B vaccine Phase II clinical trial will be completed in September 2011 all subjects were observed and then blinded,　　Subsequent Ⅲ trials will be completed within two years, and the Phase 3 clinical observation period will be shortened if the results of phase II clinical trials exceed expectations. China Securities believes that the treatment of synthetic peptides in 2014 to obtain a new drug certificate and the possibility of listing is great.　　Conservative calculation of the first year after the listing can achieve nearly 500 million yuan sales revenue and 200 million yuan net profit, after the listing of 10 years will probably have a growth rate of about 30%, resulting in tens of billions of yuan sales revenue. Therefore, the treatment of (synthetic peptide) hepatitis B vaccine, once listed will produce great social benefits and to Chongqing Brewery brings considerable profit contribution.